CLX Investment Company Announces First Shipment of Zonda Infectious Disease Test to Swedish Pharmacies.

TEMECULA, Calif. -- CLX Investment Company Inc. (OTCBB:CLXN) today announced that portfolio investment Zonda Inc., which specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets, has sent the first shipment of its HandiLab-C test for Chlamydia to be distributed in pharmacies throughout Sweden.

Zonda's HandiLab-C test, the only over-the-counter test that carries the CE mark, which signifies that the product complies with the relevant health, safety, environmental protection requirements in Europe and can therefore be legally placed on the market, is currently distributed to pharmacies across Norway and in other selected European markets. Beginning on Feb. 1, 2006, HandiLab-C test will be made available to all pharmacies in Sweden.

"Zonda has reported brisk sales of the Chlamydia diagnostic test for over-the-counter use, and we expect that by expanding distribution to Sweden, throughout Scandinavia, and to markets across Europe, Zonda's revenues will steadily increase in the coming fiscal quarters and the value of CLX's investment in Zonda will grow," said Tammy D. Dunn, chief executive officer of CLX Investment Company. "Zonda is pursuing distribution of the Chlamydia rapid test in large worldwide markets, such as the United States and China, and is concurrently establishing similar distribution channels for its other diagnostic products, including products for the detection of gonorrhea, yeast and Strep A."

Zonda Inc., a privately held company that specializes in test products that serve the medical diagnostic (IVD), food safety, and sanitation testing markets, is expanding the distribution of its product lines into broader markets around the world, beginning with a focus in Europe. The first product targeted for accelerated marketing and distribution efforts is an innovative, rapid, self-contained diagnostic device for the detection of Chlamydia, which carries a CE mark for professional and over-the-counter use. The device, which is marketed under the HandiLab-C name, is superior to its competition due to its comparable accuracy (compared directly to PCR testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness. Zonda's diagnostic testing products for the detection of gonorrhea, yeast and Strep A all carry CE marks for professional point-of-care use.

To sign up to receive information by e-mail directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About the Company

CLX Investment Company (www.clxinvestments.com) has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the company seeks to make investments in developing companies with the goal of providing return for its shareholders.

CLX has acquired a 49 percent interest in eStrategy Solutions Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. The company has made an investment in ActionView International Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. CLX holds a 20 percent equity interest in Zonda Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.